Countries with high vaccination rates and already started booster shots will likelihood continue with existing list of vaccines and will be low volume procurement just to satisfy those low % of people holding back from mRNA ones. Countries with low vaccination rates may explore alternative vaccine(s) if price is significantly cheaper. Overall, not expecting to sell in high volumes unlike mRNA ones where additional procurement to cater for booster shots already locked in or in the mist of it.